Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase

Li, Quanjie; Yi, Dongrong; Lei, Xiaobo; Zhao, Jin; Zhang, Yongxin; Cui, Xiangling; Xiao, Xia; Jiao, Tao; Dong, Xuan; Zhao, Xiongyan; Zeng, Hui; Liang, Chen; Ren, Lili; Guo, Fei; Li, Xiaoyü; Wang, Jianwei; Cen, Shan

doi:10.1016/j.apsb.2021.02.011

Cited by 45 publications

(47 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To assess if these compounds were effective against the replication of coronavirus, a cell-based assay was utilized using HCT-8 and LLC-MK2 cell line infected with coronavirus strains HCoV-OC43 and HCoV-NL63, which belong to beta coronaviruses and alphacoronaviruses, respectively, followed by measuring the protection of cell viability against CoV-induced cytopathic effect (CPE) as a read-out ( Li et al, 2021 ). Using Remdesivir as a positive control, we infected HCT-8 or LLC-MK2 cells with these two coronavirus strains at MOI of 0.1 and 0.01 respectively and then treated the cells with serial dilutions of the four compounds.…”

Section: Resultsmentioning

confidence: 99%

5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis

Zhao

Liu

et al. 2022

Antiviral Research

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a newly emerged infectious disease caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid global emergence of SARS-CoV-2 highlights the importance and urgency for potential drugs to control the pandemic. The functional importance of RNA-dependent RNA polymerase (RdRp) in the viral life cycle, combined with structural conservation and absence of closely related homologs in humans, makes it an attractive target for designing antiviral drugs. Nucleos(t)ide analogs (NAs) are still the most promising broad-spectrum class of viral RdRp inhibitors. In this study, using our previously developed cell-based SARS-CoV-2 RdRp report system, we screened 134 compounds in the Selleckchemicals NAs library. Four candidate compounds, Fludarabine Phosphate, Fludarabine, 6-Thio-20-Deoxyguanosine (6-Thio-dG), and 5-Iodotubercidin, exhibit remarkable potency in inhibiting SARS-CoV-2 RdRp. Among these four compounds, 5-Iodotubercidin exhibited the strongest inhibition upon SARS-CoV-2 RdRp, and was resistant to viral exoribonuclease activity, thus presenting the best antiviral activity against coronavirus from a different genus. Further study showed that the RdRp inhibitory activity of 5-Iodotubercidin is closely related to its capacity to inhibit adenosine kinase (ADK).

show abstract

Section: Resultsmentioning

confidence: 99%

5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis

Zhao

Liu

et al. 2022

Antiviral Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Besides, the RdRp sequences are highly conserved across different CoVs and both SARS CoV-2 and HCoV-OC43 are betacoronavirus. Herein, in this cell-based assay, both HCT-8 and LLC-MK2 cell lines were infected with HCoV-OC43 and HCoV-NL63 respectively, followed by measuring the CoV-induced cytopathic effect (CPE) inhibition as an out-put( Li et al, 2021 ). Briefly, HCT-8 or LLC-MK2 cells were pretreated with serial dilution of 4–46b and 6-72-2a for 48h, and subsequently infected with HCoV-OC43 and HCoV-NL63, respectively ( Fig.…”

Section: Resultsmentioning

confidence: 99%

2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors

Zhao

Zhang

et al. 2021

Antiviral Research

Self Cite

View full text Add to dashboard Cite

“…Corilagin, a non-nucleoside inhibitor, is a gallotannin isolated from the medicinal plant Phmllanthi Fructus [ 35 ]. Corilagin has been reported to inhibit SARS-CoV-2 infection with an EC 50 value of 0.13 μM in a concentration-dependent manner by preventing the conformational change of RdRp and inhibits SARS-CoV-2 replication [ 36 ]. Furthermore, corilagin, as identified via molecular dynamics simulation-guided studies, could also be used as an endogenous M pro candidate, with an 88% anti-SARS-CoV-2 M pro activity at concentrations of 20 μM in vitro [ 37 ].…”

Section: Natural Products As Monotherapy For the Treatment Of Sars-cov-2mentioning

confidence: 99%

Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer

Yang

Wang

2021

Biomedicines

View full text Add to dashboard Cite

As a public health emergency of international concern, the highly contagious coronavirus disease 2019 (COVID-19) pandemic has been identified as a severe threat to the lives of billions of individuals. Lung cancer, a malignant tumor with the highest mortality rate, has brought significant challenges to both human health and economic development. Natural products may play a pivotal role in treating lung diseases. We reviewed published studies relating to natural products, used alone or in combination with US Food and Drug Administration-approved drugs, active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and lung cancer from 1 January 2020 to 31 May 2021. A wide range of natural products can be considered promising anti-COVID-19 or anti-lung cancer agents have gained widespread attention, including natural products as monotherapy for the treatment of SARS-CoV-2 (ginkgolic acid, shiraiachrome A, resveratrol, and baicalein) or lung cancer (daurisoline, graveospene A, deguelin, and erianin) or in combination with FDA-approved anti-SARS-CoV-2 agents (cepharanthine plus nelfinavir, linoleic acid plus remdesivir) and anti-lung cancer agents (curcumin and cisplatin, celastrol and gefitinib). Natural products have demonstrated potential value and with the assistance of nanotechnology, combination drug therapies, and the codrug strategy, this “natural remedy” could serve as a starting point for further drug development in treating these lung diseases.

show abstract

Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase

Cited by 45 publications

References 50 publications

5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis

5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis

2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors

Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer

Contact Info

Product

Resources

About